Stereotactic Ablative Radiotherapy achieves better overall survival than surgery for early lung cancer
First randomized clinical trial comparing the two therapies suggests that the non-invasive SABR treatment should be considered an alternative to surgery, especially for elderly patients and those with comorbidities
MD Anderson News Release 05/13/2015
Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic Ablative Radiotherapy (SABR) rather...
